AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 1567042 — intervention group
Group type: EXPERIMENTAL
Intervention: Promethazine (0.625 mg/PCA dose, average of 17.6 mg/24 h)
Number of subjects: 0
Study 1567042 — intervention group
Group type: COMPARATOR
Intervention: Control (PCA with morphine only, 1.5 mg, 6-min lockout interval)
Number of subjects: 0
Study 3901826 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (ASA) 650 mg daily postoperatively
Number of subjects: 93
Study 3901826 — intervention group
Group type: COMPARATOR
Intervention: No aspirin (NASA)
Number of subjects: 93
Study 3901826 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall grafts (both ASA and NASA)
Number of subjects: 93
Study 30515560 — intervention group
Group type: EXPERIMENTAL
Intervention: SwallowIT-assisted therapy (n=26)
Number of subjects: 79
Study 30515560 — intervention group
Group type: COMPARATOR
Intervention: Clinician-directed therapy (n=26)
Number of subjects: 79
Study 30515560 — intervention group
Group type: COMPARATOR
Intervention: Patient-directed therapy (n=27)
Number of subjects: 79
Study 29696707 — intervention group
Group type: EXPERIMENTAL
Intervention: vitamin D3 (5000 IU daily) + phenylbutyrate (2 × 500 mg daily)
Number of subjects: 348
Study 29696707 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 348
Study 28446396 — intervention group
Group type: EXPERIMENTAL
Intervention: Group T1 (ropivacaine for thoracic paravertebral block)
Number of subjects: 60
Study 28446396 — intervention group
Group type: EXPERIMENTAL
Intervention: Group T2 (ropivacaine and sufentanil for thoracic paravertebral block)
Number of subjects: 60
Study 28446396 — intervention group
Group type: COMPARATOR
Intervention: Group C (control)
Number of subjects: 60
Study 24448512 — intervention group
Group type: EXPERIMENTAL
Intervention: Perineural ropivacaine 0.4%
Number of subjects: 60
Study 24448512 — intervention group
Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 60
Study 22524447 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisatracurium besylate therapy within 2 days of ARDS onset
Number of subjects: 339
Study 22524447 — intervention group
Group type: COMPARATOR
Intervention: Patients with microbiologically documented bacterial VAP
Number of subjects: 339
Study 22524447 — intervention group
Group type: COMPARATOR
Intervention: Patients without VAP
Number of subjects: 339
Study 22524447 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 339
Study 22524447 — intervention group
Group type: COMPARATOR
Intervention: Tracheostomy, enteral nutrition, and use of a subglottic secretion-drainage device
Number of subjects: 339
Study 19910624 — intervention group
Group type: EXPERIMENTAL
Intervention: IV propofol
Number of subjects: 80
Study 19910624 — intervention group
Group type: COMPARATOR
Intervention: sevoflurane
Number of subjects: 80
Study 18366490 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual administration of misoprostol (400 microg three‐hourly, up to a maximum of five doses over 24 h)
Number of subjects: 300
Study 18366490 — intervention group
Group type: COMPARATOR
Intervention: Vaginal administration of misoprostol (400 microg three‐hourly, up to a maximum of five doses over 24 h)
Number of subjects: 300
Study 18366490 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual administration of misoprostol
Number of subjects: 300
Study 18366490 — intervention group
Group type: COMPARATOR
Intervention: Vaginal administration of misoprostol
Number of subjects: 300
Study 16123481 — intervention group
Group type: EXPERIMENTAL
Intervention: Biofeedback (electromyograph and thermal) and relaxation (10 sessions)
Number of subjects: 39
Study 16123481 — intervention group
Group type: COMPARATOR
Intervention: Education (3 sessions)
Number of subjects: 39
Study 11873073 — intervention group
Group type: EXPERIMENTAL
Intervention: Efavirenz-containing regimen (group 1; 51 patients)
Number of subjects: 100
Study 11873073 — intervention group
Group type: COMPARATOR
Intervention: Protease inhibitor-containing regimen (group 2; 49 patients)
Number of subjects: 100
Study 10202784 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction chemotherapy, allogeneic or autologous bone marrow transplantation (BMT)
Number of subjects: 179
Study 10202784 — intervention group
Group type: COMPARATOR
Intervention: Randomized disclosure of collected information to staff
Number of subjects: 179
Study 7586246 — intervention group
Group type: EXPERIMENTAL
Intervention: Streptokinase/subcutaneous heparin therapy
Number of subjects: 0
Study 7586246 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination thrombolytic therapy
Number of subjects: 0
Study 7586246 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall
Number of subjects: 0
Study 7586246 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary intracranial hemorrhage
Number of subjects: 0
Study 7586246 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonhemorrhagic infarctions
Number of subjects: 0
Study 7586246 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate or severe residual deficits
Number of subjects: 0
Study 2154430 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin (250 mg bd on day 1 and 250 mg once daily on days 2-5)
Number of subjects: 190
Study 2154430 — intervention group
Group type: COMPARATOR
Intervention: Erythromycin (500 mg every 6 h for seven days)
Number of subjects: 190
Study 2154430 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin (1 g single dose or 500 mg single dose on day 1 and 250 mg once daily on days 2 and 3)
Number of subjects: 190
Study 2154430 — intervention group
Group type: COMPARATOR
Intervention: Doxycycline (100 mg every 12 h for seven days)
Number of subjects: 190
Study 2154430 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin (3-day regimen)
Number of subjects: 190
Study 426993 — intervention group
Group type: EXPERIMENTAL
Intervention: Pancuronium 0.02‐0.08 mg kg‐1
Number of subjects: 0
Study 426993 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl 0.003 mg kg‐1 plus droperidol 0.15 mg kg‐1
Number of subjects: 0
Study 426993 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl 0.003 mg kg‐1
Number of subjects: 0
Study 31422365 — intervention group
Group type: EXPERIMENTAL
Intervention: Immersive VR safety training alone
Number of subjects: 130
Study 31422365 — intervention group
Group type: EXPERIMENTAL
Intervention: Lecture‐based safety training alone
Number of subjects: 130
Study 31422365 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined immersive VR safety training and HF Tool training
Number of subjects: 130
Study 31422365 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined lecture‐based safety training and HF Tool training
Number of subjects: 130
Study 31652899 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet based on the 2010 Dietary Guidelines for Americans (DGA)
Number of subjects: 0
Study 31652899 — intervention group
Group type: COMPARATOR
Intervention: Typical American diet (TAD)
Number of subjects: 0
Study 28817507 — intervention group
Group type: EXPERIMENTAL
Intervention: Deferred consent
Number of subjects: 68
Study 28817507 — intervention group
Group type: COMPARATOR
Intervention: Prior informed consent
Number of subjects: 68
Study 25496088 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-Term Assessment of Risk and Treatability (START)
Number of subjects: 188
Study 25496088 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured Professional Judgment (SPJ)
Number of subjects: 188
Study 23517287 — intervention group
Group type: EXPERIMENTAL
Intervention: pegylated‐IFNα2a weekly or albumin‐IFNα2b every 2 weeks for up to 24 weeks
Number of subjects: 869
Study 23517287 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical therapy
Number of subjects: 869
Study 21210611 — intervention group
Group type: EXPERIMENTAL
Intervention: Didactic plus role-play
Number of subjects: 115
Study 21210611 — intervention group
Group type: COMPARATOR
Intervention: Didactic instruction alone
Number of subjects: 115
Study 18364324 — intervention group
Group type: EXPERIMENTAL
Intervention: Pineapple
Number of subjects: 10
Study 18364324 — intervention group
Group type: EXPERIMENTAL
Intervention: Papaya
Number of subjects: 10
Study 18364324 — intervention group
Group type: EXPERIMENTAL
Intervention: Watermelon
Number of subjects: 10
Study 18364324 — intervention group
Group type: EXPERIMENTAL
Intervention: Durian
Number of subjects: 10
Study 18364324 — intervention group
Group type: COMPARATOR
Intervention: Glucose (reference food)
Number of subjects: 10
Study 16287396 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Processing Therapy for Sexual Abuse Survivors (CPT‐SA)
Number of subjects: 71
Study 16287396 — intervention group
Group type: COMPARATOR
Intervention: Minimal Attention (MA)
Number of subjects: 71
Study 12147834 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary fecal tagging (FT)
Number of subjects: 100
Study 12147834 — intervention group
Group type: COMPARATOR
Intervention: Standard non-FT colonic cleansing
Number of subjects: 100
Study 10824344 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of New Zealand cardiovascular risk tables
Number of subjects: 0
Study 8788692 — intervention group
Group type: EXPERIMENTAL
Intervention: Day treatment (intensive seven-day-a-week neurobehavioral treatment model program)
Number of subjects: 0
Study 8788692 — intervention group
Group type: COMPARATOR
Intervention: Traditional outpatient treatment (conventional five-day-a-week program)
Number of subjects: 0
Study 2405746 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled pirbuterol
Number of subjects: 133
Study 2405746 — intervention group
Group type: COMPARATOR
Intervention: Metaproterenol
Number of subjects: 133
Study 155297 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of beta 2-sympathomimetic (salbutamol or fenoterol) and SCH 1000
Number of subjects: 33
Study 155297 — intervention group
Group type: COMPARATOR
Intervention: SCH 1000 alone
Number of subjects: 33
Study 155297 — intervention group
Group type: EXPERIMENTAL
Intervention: SCH 1000
Number of subjects: 33
Study 31076365 — intervention group
Group type: EXPERIMENTAL
Intervention: Trebananib plus carboplatin and paclitaxel
Number of subjects: 1015
Study 31076365 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus carboplatin and paclitaxel
Number of subjects: 1015
Study 31076365 — intervention group
Group type: EXPERIMENTAL
Intervention: Trebananib
Number of subjects: 1015
Study 31076365 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1015
Study 29235507 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide (GLP-1 analog), 6 months treatment
Number of subjects: 38
Study 29235507 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 25539240 — intervention group
Group type: EXPERIMENTAL
Intervention: IV hyoscine butylbromide before examination with manual carbon dioxide insufflation
Number of subjects: 224
Study 25539240 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated carbon dioxide insufflation (no bowel relaxant)
Number of subjects: 224
Study 25539240 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined (hyoscine butylbromide before examination with automated carbon dioxide insufflation)
Number of subjects: 224
Study 25539240 — intervention group
Group type: COMPARATOR
Intervention: Control (no bowel relaxant and IV saline placebo before CT colonography with manual carbon dioxide insufflation)
Number of subjects: 224
Study 23886886 — intervention group
Group type: EXPERIMENTAL
Intervention: Action Observation Therapy (AOT) - observing video sequences of unimanual or bimanual goal-directed actions for 1 hour per day for 3 weeks followed by execution of observed actions
Number of subjects: 24
Study 23886886 — intervention group
Group type: COMPARATOR
Intervention: Control group - performed the same actions but watched computer games instead of action videos
Number of subjects: 24
Study 21402628 — intervention group
Group type: EXPERIMENTAL
Intervention: 24% sucrose solution orally
Number of subjects: 330
Study 21402628 — intervention group
Group type: COMPARATOR
Intervention: 1 g of liposomal lidocaine cream topically
Number of subjects: 330
Study 21402628 — intervention group
Group type: EXPERIMENTAL
Intervention: sucrose and liposomal lidocaine
Number of subjects: 330
Study 19359148 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium supplementation (12.3 mmol or 300 mg of elemental magnesium in the form of magnesium oxide, n=75)
Number of subjects: 155
Study 19359148 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=80)
Number of subjects: 155
Study 19359148 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium supplementation (subgroup analysis, n=8, 27, and 24 for different BP categories)
Number of subjects: 155
Study 19359148 — intervention group
Group type: COMPARATOR
Intervention: Placebo (subgroup analysis, n=16, 29, and 25 for different BP categories)
Number of subjects: 155
Study 17349076 — intervention group
Group type: EXPERIMENTAL
Intervention: Lightly cooked broccoli (microwaved 2.0 min)
Number of subjects: 12
Study 17349076 — intervention group
Group type: COMPARATOR
Intervention: Fully cooked broccoli (microwaved 5.5 min)
Number of subjects: 12
Study 17349076 — intervention group
Group type: EXPERIMENTAL
Intervention: Meat-containing meal with mustard (3 g)
Number of subjects: 12
Study 17349076 — intervention group
Group type: COMPARATOR
Intervention: Non meat-containing meal with mustard (3 g)
Number of subjects: 12
Study 15035837 — intervention group
Group type: EXPERIMENTAL
Intervention: UltraCision harmonic scalpel (UHS)
Number of subjects: 200
Study 15035837 — intervention group
Group type: COMPARATOR
Intervention: Conventional clamp-and-tie technique
Number of subjects: 200
Study 11392607 — intervention group
Group type: EXPERIMENTAL
Intervention: rhG‐CSF (filgrastim)
Number of subjects: 80
Study 11392607 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 10356434 — intervention group
Group type: EXPERIMENTAL
Intervention: Dental Anxiety Scale (DAS)
Number of subjects: 350
Study 10356434 — intervention group
Group type: EXPERIMENTAL
Intervention: Experience with dental injections
Number of subjects: 350
Study 10356434 — intervention group
Group type: EXPERIMENTAL
Intervention: DAS scores
Number of subjects: 350
Study 10356434 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical avoidance and anxiety scores
Number of subjects: 350
Study 7989975 — intervention group
Group type: EXPERIMENTAL
Intervention: Radioiodine therapy (0.85‐9.55 GBq or 23‐258 mCi of 131I)
Number of subjects: 87
Study 2670220 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE inhibitors (captopril, enalapril, quinapril)
Number of subjects: 0
Study 2670220 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE inhibitors
Number of subjects: 0
Study 30359869 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga intervention
Number of subjects: 344
Study 30359869 — intervention group
Group type: COMPARATOR
Intervention: Physical education control
Number of subjects: 344
Study 28719834 — intervention group
Group type: EXPERIMENTAL
Intervention: d3-GHR group (d3/fl and d3/d3)
Number of subjects: 96
Study 28719834 — intervention group
Group type: COMPARATOR
Intervention: fl/fl-GHR group
Number of subjects: 96
Study 28719834 — intervention group
Group type: EXPERIMENTAL
Intervention: After one year of GH therapy
Number of subjects: 96
Study 25150178 — intervention group
Group type: EXPERIMENTAL
Intervention: Bosentan treatment for 12 weeks
Number of subjects: 52
Study 25150178 — intervention group
Group type: COMPARATOR
Intervention: Healthy subjects (control group)
Number of subjects: 52
Study 23571718 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid on-site cytologic evaluation (ROSE) during EBUS-TBNA
Number of subjects: 108
Study 23571718 — intervention group
Group type: COMPARATOR
Intervention: Non-ROSE during EBUS-TBNA
Number of subjects: 108
Study 21621796 — intervention group
Group type: EXPERIMENTAL
Intervention: HADS anxiety (HADS-A) score at baseline
Number of subjects: 120
Study 21621796 — intervention group
Group type: EXPERIMENTAL
Intervention: HADS depression (HADS-D) score at baseline
Number of subjects: 120
Study 21621796 — intervention group
Group type: EXPERIMENTAL
Intervention: HADS anxiety (HADS-A) score at six months
Number of subjects: 120
Study 21621796 — intervention group
Group type: EXPERIMENTAL
Intervention: HADS depression (HADS-D) score over time
Number of subjects: 120
Study 18327133 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitrectomy with ILM peeling
Number of subjects: 38
Study 18327133 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitrectomy with ILM peeling followed by IVTA injection
Number of subjects: 38
Study 18327133 — intervention group
Group type: COMPARATOR
Intervention: Vitrectomy
Number of subjects: 38
Study 16916051 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic active hepatitis C patients
Number of subjects: 100
Study 11161933 — intervention group
Group type: COMPARATOR
Intervention: 12-lead ECG
Number of subjects: 54
Study 11161933 — intervention group
Group type: EXPERIMENTAL
Intervention: Body surface mapping
Number of subjects: 54
Study 9678318 — intervention group
Group type: COMPARATOR
Intervention: Mattis Dementia Rating Scale Memory subscale (AD group)
Number of subjects: 46
Study 9678318 — intervention group
Group type: COMPARATOR
Intervention: Initiation/Perseveration subscale (LBV group)
Number of subjects: 46
Study 9678318 — intervention group
Group type: COMPARATOR
Intervention: Attention, Construction, Conceptualization subscales
Number of subjects: 46
Study 9678318 — intervention group
Group type: COMPARATOR
Intervention: Construction subscale (mild-to-moderate dementia subgroup)
Number of subjects: 46
Study 7977090 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine, 5 mg once daily
Number of subjects: 46
Study 7977090 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide mononitrate (ISMN), 20 mg twice daily
Number of subjects: 46
Study 7977090 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine
Number of subjects: 46
Study 7977090 — intervention group
Group type: COMPARATOR
Intervention: ISMN
Number of subjects: 46
Study 3197098 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydroergotamine (10 mg) + Acetylsalicylic acid (80 mg)
Number of subjects: 45
Study 3197098 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 29468817 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mL regular coffee containing 34.8 μmol nicotinic acid (NA) and 0.58 μmol nicotinamide (NAM)
Number of subjects: 0
Study 25834948 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-mg idursulfase-IT
Number of subjects: 16
Study 25834948 — intervention group
Group type: EXPERIMENTAL
Intervention: 30-mg idursulfase-IT
Number of subjects: 16
Study 25834948 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-mg idursulfase-IT
Number of subjects: 16
Study 25834948 — intervention group
Group type: COMPARATOR
Intervention: no treatment
Number of subjects: 16
Study 25834948 — intervention group
Group type: EXPERIMENTAL
Intervention: surgical revision/removal of the IDDD
Number of subjects: 16
Study 24835417 — intervention group
Group type: EXPERIMENTAL
Intervention: EMD + DBBM
Number of subjects: 40
Study 24835417 — intervention group
Group type: COMPARATOR
Intervention: CM + DBBM
Number of subjects: 40
Study 22336901 — intervention group
Group type: EXPERIMENTAL
Intervention: Custom-made orthesis and shoes as part of a structured prevention program (Group B)
Number of subjects: 298
Study 22336901 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (Group A)
Number of subjects: 298
Study 19892540 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium 18μg inhalation capsules once daily
Number of subjects: 22
Study 19892540 — intervention group
Group type: COMPARATOR
Intervention: Placebo inhalation capsules once daily
Number of subjects: 22
Study 18375477 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma butyrylcholinesterase (BuChE) activity <600 mU/ml in chlorpyrifos poisoning
Number of subjects: 299
Study 18375477 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma butyrylcholinesterase (BuChE) activity <600 mU/ml in dimethoate poisoning
Number of subjects: 299
Study 18375477 — intervention group
Group type: EXPERIMENTAL
Intervention: High organophosphorus (OP) concentration on admission
Number of subjects: 299
Study 15976380 — intervention group
Group type: EXPERIMENTAL
Intervention: FENO group (n=39)
Number of subjects: 85
Study 15976380 — intervention group
Group type: COMPARATOR
Intervention: Symptom group (n=46)
Number of subjects: 85
Study 15976380 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 85
Study 11430713 — intervention group
Group type: EXPERIMENTAL
Intervention: Group motor skill intervention, once weekly for 10 weeks
Number of subjects: 37
Study 11430713 — intervention group
Group type: COMPARATOR
Intervention: Control subgroup (no intervention), n = 20
Number of subjects: 37
Study 9566656 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin treatment (2.5 to 7.5 mg based on body weight)
Number of subjects: 9
Study 9566656 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin treatment
Number of subjects: 9
Study 9566656 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 9
Study 8110567 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% ropivacaine 10 ml
Number of subjects: 91
Study 8110567 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% ropivacaine 20 ml
Number of subjects: 91
Study 8110567 — intervention group
Group type: COMPARATOR
Intervention: 0.5% bupivacaine 20 ml
Number of subjects: 91
Study 8110567 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 91
Study 3294080 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastric bubble
Number of subjects: 23
Study 3294080 — intervention group
Group type: COMPARATOR
Intervention: Sham procedure
Number of subjects: 23
Study 31144121 — intervention group
Group type: EXPERIMENTAL
Intervention: Timed colonoscopy with fixed withdrawal times (Group A)
Number of subjects: 1149
Study 31144121 — intervention group
Group type: COMPARATOR
Intervention: Conventional withdrawal (Group B)
Number of subjects: 1149
Study 31144121 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 1149
Study 30296845 — intervention group
Group type: EXPERIMENTAL
Intervention: Group-Early Start Denver Model in inclusive setting
Number of subjects: 44
Study 30296845 — intervention group
Group type: EXPERIMENTAL
Intervention: Group-Early Start Denver Model in specialized setting
Number of subjects: 44
Study 30296845 — intervention group
Group type: EXPERIMENTAL
Intervention: Group-Early Start Denver Model (both settings)
Number of subjects: 44
Study 27352003 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (50 μg kg−1) and midazolam (0.45 mg kg−1)
Number of subjects: 16
Study 27352003 — intervention group
Group type: COMPARATOR
Intervention: Dexmedetomidine (30 μg kg−1), midazolam (0.45 mg kg−1) and butorphanol (0.25 mg kg−1)
Number of subjects: 16